Xenon detection in human blood: Analytical validation by accuracy profile and identification of critical storage parameters. by Frampas, C. et al.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: Xenon detection in human blood: Analytical validation by accuracy
profile and identification of critical storage parameters.
Authors: Frampas C, Ney J, Coburn M, Augsburger M, Varlet V
Journal: Journal of forensic and legal medicine
Year: 2018 Aug
Issue: 58
Pages: 14-19
DOI: 10.1016/j.jflm.2018.04.005
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
Xenon detection in human blood: analytical validation by accuracy profile and 
identification of critical storage parameters 
Authors : 
Cécile FRAMPAS
1
, Julia NEY
2
, Mark COBURN
2
, Marc AUGSBURGER
1
, Vincent
VARLET
1*
Addresses: 
1. Forensic Toxicology and Chemistry Unit, University Centre of Legal Medicine Lausanne-
Geneva, Lausanne, Switzerland 
2. Department of Anaesthesiology, University Hospital RWTH, Aachen, Germany
*Corresponding author: Vincent Varlet
Telephone:  0041795566293 
Vincent.varlet@chuv.ch 
The authors report no conflict of interest
Title Page (WITH Author Details)
Xenon detection in human blood: analytical validation by accuracy profile and 
identification of critical storage parameters 
Abstract 
Xenon is a rare, mostly inert, noble gas that has applications in a wide range of fields, including 
medicine. Xenon acts on the human body as a useful organ-protective and anesthetic agent and 
has also been previously studied for potential applications in fields such as optics, aerospace and 
medical imaging. Recently, it was discovered that xenon can boost erythropoietin production, 
and it has been used as a performance-enhancing agent in international sports competitions such 
as the Sochi Olympic Games. Therefore, screening methods to detect the misuse of xenon by 
analysis of biological samples and to monitor anesthesia kinetics and efficiency are being 
investigated. The aim of this study was to develop and validate an analytical method to detect 
xenon in blood samples using gas chromatography coupled to tandem mass spectrometry (GC-
MS/MS).  
Preliminary studies were conducted to determine the best parameters for chromatography and 
mass spectrometry for xenon. The analysis was performed using the multiple reaction monitoring 
(MRM) mode using the transitions m/z 129→129, 131→131 for xenon and 84→84, 86→86 for 
krypton, which was chosen as the internal standard. The LOD of GC-MS/MS was found to be 52 
pmol on-column. Calibration lines and controls were made to obtain an accuracy profile at a 
range of 2.08–104 nmol with a β-expectation tolerance interval set at 80% and the acceptability 
limit set at ±30%. From the accuracy profile, the LOQ of 15 nmol on-column for the range of 
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2.08–104 nmol was obtained. The method was validated according to the guidelines of the 
French Society of Pharmaceutical Sciences and Techniques. 
The detection method was finally validated using blood from test persons subjected to a 15% or 
30% xenon mixture with pure oxygen and air for 45 minutes. Even though the probes were 
already used for other projects, it was still possible to detect xenon.  
Keywords: xenon; anaesthesia; anti-doping; accuracy profile; blood analysis; GC-MS/MS 
Introduction 
Xenon is a noble gas that was initially found in very small amounts (0.087 ppm) in the 
composition of liquid air in 1898, and this element possesses some interesting physiological 
properties.
1
 In 1939, it was discovered that xenon can act as an anesthetic agent, and in 1951, the
first surgery with xenon was performed.
2,3
 Since then, much research has been conducted on this
gas to better understand its mechanism of action in the body.
4-7
 In addition to its anesthetic
properties, xenon has organ-protective properties that may be based on its interaction with the 
hypoxia-inducible factor HIF-1α.8,9 When this factor is activated, it increases the synthesis of
erythropoietin (EPO), a substance commonly used in doping.
10,11
 For this reason, the World
Anti-doping Agency (WADA) decided to ban the use of this substance in September 2014. The 
determination of xenon in human blood is therefore of practical interest for medical anesthesia 
and doping control.  
The absorption, distribution, metabolism and excretion of xenon are very simple, but 
descriptions of these processes in the literature are scarce. According to a recent study on xenon 
elimination kinetics following brief exposure, xenon is inhaled through the lungs and reaches all 
of the compartments (i.e., lungs, brain, liver, muscle, tissues, and fat tissues). The gas is not 
metabolized, and once the patient stops inhaling the gas, it washes out quickly and is mainly 
excreted during two phases, which is typical for substances stored in multiple compartments, 
including anesthetics.
12
 The first phase leads to xenon elimination of approximately 95%, which
is exhaled in the first pass by the lungs and shows a half-life of 2.7 h.
13-15
 The second phase,
which is much slower and results from residual amounts of xenon, is expressed by a non-linear 
regression characterized by first-order kinetics and could be related to body fat content due to the 
solubility of xenon in fat matter.  
Xenon gas is not metabolized by the body and is rapidly eliminated, and analysis of this gas 
requires analytical methods with high sensitivity because the xenon concentration measured in 
blood is usually in the nmol/mL range (ppb). However, the concentrations of xenon used for 
anesthesia are higher than those used for doping purposes and are easier to measure. For 
example, xenon can be detected in blood up to 30 h after storage and in urine until 40 h post-
anaesthesia.
16,17
 Consequently, gas chromatography coupled to mass spectrometry (GC-MS) and
tandem mass spectrometry (GC-MS/MS) seem to be the best candidates for detection, and these 
methods have already been investigated.
16-18
 To this end, MS/MS may be more efficient because
even if no fragmentation occurs, the energy of collision can be applied to reduce background 
noise. As no cut-offs have been set for this substance, the first analytical step is to detect xenon 
in biological samples, and the next is to provide an estimation of the concentration even if the 
physiological significance remains unknown.  
The aim of this study was to develop and validate an analytical method to detect xenon in 
biological samples. GC-MS/MS is the most appropriate method because it combines high 
separation power from GC with high selectivity from tandem mass spectrometry, which allows 
the background interference to be minimized and improves both the selectivity and sensitivity. 
The validation step involves demonstrating that the analytical method is appropriate, reliable and 
precise for this potential use. Subsequently, this method was applied to biological samples 
obtained from study subjects after xenon inhalation to determine whether it was possible to 
detect this substance in the samples.  
Experimental design 
Materials 
Xenon (purity, 4.0) and krypton (purity, 4.0) were purchased from Carbagas AG (Lausanne, 
Switzerland) and PanGas AG (Dagmersellen, Switzerland), respectively. Bovine blood samples 
for blanks were obtained from the Forensic Toxicology and Chemistry Unit at the University 
Center of Legal Medicine (Lausanne, Switzerland). 
Authentic blood samples were obtained from three volunteers from the University Hospital 
RWTH Aachen (Germany) as part of a study on male and Caucasian test persons older than 18 
years submitted to 30% or 15% xenon for 45 minutes. The study was registered at the European 
Medicines Agency (EudraCT-number: 2014-000973-38), at ClinicalTrials.gov (NCT number: 
02129400) and has been published.
11
 For this intervention, Xenon pro Anesthesia from Air
Liquide (Düsseldorf, Germany) and oxygen (Conoxia) from Linde AG (München, Germany) 
were used. The car bulb containing xenon (M-Tech Basic D1S 4300) was purchased at 
AutoCouture (Cugy, Switzerland). The airtight gas syringes were purchased from Vici (Baton 
Rouge, USA); the gas-tight vials (20 mL), from Agilent (BGB Analytic SA, Genève); and EDTA 
tubes (2.7 mL), from Sarstedt (Nümbrecht, Germany). 
Instruments and conditions 
The analyses were conducted on a Varian CP-3800 gas chromatograph (Walnut Creek, CA, 
USA) coupled to a Varian 1200L MS/MS triple quadrupole mass spectrometer (Walnut Creek, 
CA, USA) operating in electron ionization (EI) mode (70 eV).  
The compounds were separated on a series of two columns, a fused silica Restek Rxi®-624Sil 
MS column (midpolarity Crossbond® silarylene phase) similar to a 6% cyanopropylphenyl/94% 
dimethylpolysiloxane stationary phase (30 m length × 0.25 mm I.D. × 1.4 µm film thickness) 
coupled inline to an Agilent J&W (DB-624) with 6% cyanopropylphenyl/94% dimethyl 
polysiloxane stationary phase (30 m length × 0.32 mm I.D. × 1.8 µm film thickness).  
The instrument temperature was 250°C for the transfer line and injector and 160°C for the ion 
source. Injections were conducted manually with an airtight gas syringe in splitless mode. The 
initial oven temperature of 40°C was held for 3 minutes, increased by 20°C/minute to 120°C and 
then kept at this temperature for 2 minutes. The carrier gas was helium with a constant flow of 
2.5 mL/minute. 
The GC-MS/MS was operated in selected ion monitoring (SIM) mode with the ions m/z 84 and 
86 for krypton and m/z 129 and 131 for xenon for both of the quadrupoles and isolated with ±0.7 
amu. The ion source temperature was kept at 160°C. The collision energy was maintained at 20 
eV for the transitions m/z 84→84, 86→86, 129→129 and 131→131 (there was no fragmentation 
but a mass cleanup), and the electron multiplier was set to 1 000 V. Argon was used as the 
collision gas at a pressure of 2.19 mTorr.  
Retention times were 4.06 minutes for xenon and 3.95 minutes for krypton. 
Data acquisition and MS controls were obtained using the software Varian MS Workstation 
6.9.3. 
Samples used for validation 
Calibration samples 
Calibration samples were prepared with appropriate volumes of standard xenon and krypton 
dilutions (1 040 nmol/mL and 52 nmol/mL for xenon; 1 040 nmol/mL for krypton) to obtain six 
different amounts of xenon injected ranging from 2.08 nmol to 104 nmol (2.08, 5.2, 10.4, 26, 52 
and 104 nmol injection volumes). In total, 52 nmol of the internal standard krypton was also 
added in the gas syringe before injection of each sample. The calibration range was chosen 
considering the limits of detection for analytical methods of xenon measurement in biological 
samples, which were already published.
16-18
Quality control samples 
Quality control samples were prepared with the appropriate volumes of standard xenon and 
krypton dilutions (728 nmol/mL and 72.8 nmol/mL for xenon; 1 040 nmol/mL for krypton) to 
obtain five different injection volumes of xenon ranging from 3.64 to 72.8 nmol (3.64, 7.28, 
18.2, 36.4 and 72.8 nmol injection volumes). As for the calibration samples, 52 nmol of krypton 
was added to the gas syringe before injection of each sample. 
Validation procedure 
The method was validated according the guidelines of the “Société Française des Sciences et 
Techniques Pharmaceutiques” (SFSTP) commission in 2003-2006.19 The validation was made
with the calibration samples and quality control samples each repeated three times and 
performed on three non-consecutive days. The parameters considered for the validation were 
selectivity, calibration curve, linearity, trueness, precision, accuracy, LOD and LOQ to finally 
obtain an accuracy profile.  
The approach was based on the use of a β-expectation interval tolerance of 80%, meaning that 
the intervals for each experimental point contain an average of 80% of the total values.
20
 The
tolerance intervals (TI) were defined as TI = X ± k × √ (S2r + S
2
R), where S
2
r is the standard
deviation of repeatability and S
2
R is the standard deviation of reproducibility. In the β-
expectation interval tolerance approach, k = tᵥ × √(1 + [1 / (I × J × B2)]), where I is number of
series, J is the number of repetitions, and B
2
 is a coefficient. This coefficient is given as B
2
 = (R
+ 1) / [J × (R + 1)] with R = S
2
r / S
2
R. tᵥ is Student’s coefficient with degrees of freedom ν
defined as ν = (R + 1)2 / {[(R + 1 / J)2 / (I – 1)] + [(1 - 1/J) / (I × J)]}.
Headspace storage stability study 
Bovine blood was placed in six EDTA tubes, and the tube headspaces were fortified with xenon 
(168 nmol/mL of blood) by direct injection of gas into the headspaces of the tubes through the 
septum. All of the tubes were then stored in different places and at different temperatures. One 
tube was stored at room temperature; one at 4°C; one in a car trunk that was later submitted to a 
1 000-km trip under car temperature for two weeks; and three, at -20°C. GC-MS/MS analyses 
were conducted on four of the samples (room temperature, 4°C, car trunk and -20°C) on the first 
day and then after two weeks to evaluate the influence of storage temperature and transport on 
xenon in blood.  
GC-MS/MS analyses were conducted on the three samples stored at -20°C to check the influence 
of freezing/thawing cycles. One sample was thawed and analyzed three times; another, two 
times; and the last, only once.  
Analyses of human biological samples 
Seventeen frozen EDTA tubes containing blood from 3 study test persons after inhalation of 
xenon (30% of xenon mixed with 60% oxygen and 10% air for two volunteers and 15% of xenon 
mixed with 75% oxygen for the other) for 45 minutes were provided by the Department of 
Anaesthesiology at the University Hospital RWTH, Aachen, Germany; the blood samples were 
collected at different sampling times (directly after, 2 h, 4 h, 8 h, 24 h and 48 h after the 
intervention).
11
 To analyze these samples, the EDTA tubes were weighed, and the empty tube
weight value was subtracted from the total weight to obtain the blood mass and volume and then 
the headspace volume. Then, 100 µL of the headspace was sampled and injected in the presence 
of the internal standard.  
Results and discussion 
Limit of detection (LOD) 
The LOD was evaluated by analyzing gas-tight vials containing various decreasing 
concentrations of xenon. The LOD was considered the lowest analyte concentration that has been 
evaluated to give a minimal signal-to-noise ratio (S/N) of 3 over at least ten repetitions. The 
LOD was then calculated at 52 pmol on-column. 
Response function 
The response function is described by the relationship between the amount of xenon in the 
sample and the area ratio of xenon to krypton (analyte to internal standard ratio) within the range 
of the amount and was defined using calibration samples. Three calibration curves were made on 
three non-consecutive days (p=3) at six levels (k=6): 2.08, 5.2, 10.4, 26, 52 and 104 nmol; each 
was repeated three times (n=3). For these calibration curves, a linear relationship (y= ax+b) was 
established between the amount injected and the area ratio of xenon to krypton.  
Linearity 
To test the linearity of the method, a linear regression was applied between the back-calculated 
xenon levels from the quality control samples and the theoretical levels. The quality control 
samples were measured for five amounts of xenon injected (k=5), and each was repeated three 
times (n=3) on three non-consecutive days (p=3) (Table 1). The coefficient of linear correlation 
for the range [2.08–104 nmol] was found to be satisfactory.  
For the range of 2.08–104 nmol, both the calibration point and controls were close to the 
calibration line for the three non-consecutive days, which led to satisfactory correlation 
coefficients. It should be noted that all of the injections were carried out manually so the results 
obtained could be considered satisfactory. 
Trueness 
The trueness or bias is the difference between the estimator's expected value and the true value of 
the parameter being estimated. The values are shown in Table 1. 
According to these values, this method is accurate above 7.28 nmol for the range of 2.08–104 
nmol. 
Precision: repeatability and intermediate precision 
The precision was obtained by conducting multiple analyses of the same sample on three 
different days and is expressed by the CVr and CVR. This value was calculated using 
repeatability (intra-day precision) and intermediate precision (inter-day precision) at each quality 
control amount of xenon. The repeatability component of the variance was estimated by 
measuring intra-day variance, and the intermediate precision component of the variance was 
obtained from the inter-day variance. The values are shown in Table 1. 
Accuracy and limit of quantification (LOQ) 
The general term ‘accuracy’ is used to describe the closeness of a measurement to the true value 
and is the sum of systematic error (trueness) and random error (precision). The accuracy profile 
of xenon was established according to the proposals of the SFSTP for the harmonization of 
analytical method validation
19
 with a β-expectation tolerance interval set at 80% (Figure 1).
From the accuracy profile, the LOQ was defined as 15 nmol on-column for the range of 2.08–
104 nmol.  
Selectivity 
To test the xenon chromatogram selectivity, GC-MS/MS analyses in SCAN mode (50-150 amu) 
were conducted with xenon in presence of numerous gases: argon (M=39.9 g/mol), nitrous oxide 
(M=44 g/mol), 3.2 LPG (25% propane, 55% butane and 20% isobutane, M=44.1 and 58.1 g/mol) 
and a gas (containing H2, CH4, H2S, CO2, N2 and O2) from the abdominal cavity of an altered 
body.  
According to the chromatogram, there were no artifacts or interferences from these gases with 
xenon. 
Another screening in SCAN mode (50–150 amu) was made with xenon, krypton and the 
following volatile compounds: dichloromethane (M=84.9 g/mol), trichloroethane (M=133.4 
g/mol) and trichloroethylene (M=131.4 g/mol). These solvents were chosen due to their similar 
m/z values compared with xenon and krypton, and they were diluted in mineral oil to obtain a 
concentration of 2 g/L and heated at 80°C for ten minutes.  
Then, a screening in SIM mode was performed with the same mixture (xenon, krypton, 
dichloromethane, trichloroethane and trichloroethylene) with the specific ion transitions of xenon 
and krypton (84→84, 86→86, 129→129 and 131→131) with a larger time range. The 
chromatogram is shown in Figure 2. 
According to these chromatograms, even if the volatile compounds had similar m/z values, they 
did not interfere with xenon and krypton. With these GC parameters, dichloromethane has a 
retention time of 7.35 minutes; trichloroethane, of 8.97 minutes; and trichloroethylene, of 9.74 
minutes, while the peaks of xenon and krypton had retention times of 4.06 and 3.95 minutes, 
respectively, so there is no coelution. The chromatogram and mass spectra are specific to xenon. 
The methods have been applied to a car bulb containing xenon (M-tech Basic D1S 4300) as an 
external quality control for xenon detection. The method was practical for the car bulb and 
showed the 129 and 131 ions of xenon. Nonetheless, due to the unknown volume and pressure in 
the bulb, it was not possible to determine the amount of xenon contained within.  
Storage stability 
The influence of storage for 15 days was evaluated with four samples analyzed by GC-MS/MS 
on day 0 and again after two weeks. Losses of xenon in frozen samples (-20°C) were the weakest 
(only 2% xenon). Losses of xenon in samples stored in fridge (4°C), at room temperature (close 
to 22°C) or at environmental temperature (day temperature > 25°C, night temperature > 15°C) 
experienced greater losses at 61, 77 and 98%, respectively. 
However, a more complete study of stability should be carried out on additional samples to 
confirm these results. Considering the gaseous nature of xenon, frozen storage should be the best 
storage to prevent xenon loss.  
Similarly, the influence of freezing/thawing cycles without tube opening was studied for 15 days. 
The loss of xenon after three cycles was approximately 50%. Of course, to prevent xenon loss, it 
is desirable to reduce freeze/thaw cycles to the minimum number possible. The loss of xenon 
could also be due to thermal influence on the airtightness of the rubber septa of blood tubes that 
have been already pierced for the fortification. 
Analyses of human biological samples  
It should be noted that all samples were from a 2015 study and had therefore already been 
analyzed, which implies that the tubes were likely opened or penetrated by needles through the 
septum; thus, there was no longer a guarantee of airtightness. The total storage period was 
between 6 and 18 months. Therefore, the goal of this application was more focused on the 
possibility of detecting xenon in human blood under sub-optimal conditions rather than 
providing precise xenon concentrations. In addition, even though thawing did not strongly 
impact xenon content, it was still a source of xenon loss (approximately 2% by freezing/thawing) 
as were the freezing/thawing cycles.  
Xenon was detected in 15 samples out of 17. A chromatogram from one of the volunteers 
subjected to xenon anesthesia is shown in Figure 3. 
The results of the analyses of the blood samples are shown in Table 2. As expected, the probes 
taken directly after chirurgical intervention had the highest xenon concentration, and the 
maximum was detected in volunteer 2. However, as the conditions of the analyses by the 
University Hospital RWTH are not entirely known and the tubes were already used, it is difficult 
to draw conclusions regarding the concentrations. However, these measurements were useful for 
evaluating the efficiency of detection for xenon.  
As a result, the method was shown to be practical for detecting xenon in human blood probe 
samples up to 48 h after the intervention and after storage under freezing for several months.  
As no cut-offs have been set until now, we recommend the use of this method only for detection 
to diagnose xenon misuse in doping. The method presented herein is one of the most sensitive 
methods for xenon detection considering an LOD of 52 pmol on-column. Although the 
concentrations used to induce medical anesthesia are much higher, the calibration range [2.08–
104 nmol] is satisfactory for monitoring xenon elimination after xenon exposure. 
Conclusions 
In this study, a selective and sensitive method of xenon detection was developed and validated 
using GC-MS/MS. The method was validated using accuracy profiles and according to the 
guidelines of the French Society of Pharmaceuticals Sciences and Techniques (SFSTP). The 
validity of the method was tested using blood from healthy study test persons receiving sub-
anesthetic doses of xenon by inhalation. The gas was reliably detected in nearly all the probes 
even though they were already used. As no cut-offs have been set until now and detection is only 
recommended to diagnose xenon misuse in doping, the method presented herein is one of the 
most sensitive for xenon detection considering an LOD of 52 pmol on-column. Because the 
concentrations used to induce medical anesthesia are much higher, the calibration range [2.08–
104 nmol] is satisfactory, and the method provided accurate and reliable estimates over a xenon 
range of 15 to 104 nmol, which demonstrates the applicability of the method for xenon 
elimination monitoring after exposure.  
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Figure legends 
Fig. 1: Accuracy profile for the range of 2.08–104 nmol with a β-expectation tolerance interval 
set at 80% and acceptance limit at ±30% 
Fig. 2: Screening in SIM mode with krypton, xenon, dichloromethane, trichloroethane, 
trichloroethylene and the ion transitions 84→84, 86→86, 129→129 and 131→131 
Fig. 3: Chromatograms coming from volunteer 2 (30% xenon/60% oxygen/10% air for 45 
minutes) immediately after inhalation of xenon 
Figure 1: Accuracy profile for the range of 2.08–104 nmol with a β-expectation tolerance 
interval set at 80% and acceptance limit at ±30% 
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Figure 2: Screening in SIM mode with krypton, xenon, dichloromethane, trichloroethane, and 
trichloroethylene and with the ion transitions 84→84, 86→86, 129→129 and 131→131 
Figure 3: Chromatograms coming from volunteer 2 (30% xenon/60% oxygen/10% air for 45 
minutes) immediately after inhalation of xenon 
Table 1. Results from the method validation 
Range [2.08–104 nmol] 
Day 1 Day 2 Day 3 
Slope 0.262 0.045 0.041 
Intercept - 0.456 0.089 0.058 
R
2
0.996 0.992 0.991 
Range [2.08–104 nmol] 
Target value 3.64 7.28 18.2 36.4 72.4 
Level average 2.033 3.987 21.26 39.37 72.28 
Bias - 44% - 45% 17% 8% - 1% 
Lower limit 0.998 2.641 19.27 36.00 69.93 
Upper limit 3.068 5.334 23.26 42.73 74.64 
CVr 23.77% 15.77% 6.34% 5.43% 2.28% 
CVR 23.70% 16.15% 6.35% 5.19% 2.11% 
Table 2. Results of the analyses of blood samples from patients after exposure to xenon 
anesthesia (LOD: 52 pmol, LOQ: 15 nmol) 
(nmol/mL 
of blood) 
Directly 
after 
2 h 4 h 8 h 24 h 48 h 
Volunteer 
1 
19 No sample < LOQ < LOQ < LOQ < LOQ 
Volunteer 
2 
130 < LOQ < LOQ < LOQ < LOQ < LOQ 
Volunteer 
3 
22 < LOQ < LOQ < LOQ Not 
detected 
Not 
detected 
Figure 1: Accuracy profile for the range 2.08-104 nmol with a β-expectation tolerance interval 
set at 80% and acceptance limit at ±30% 
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Figure 2: Screening in SIM mode with krypton, xenon, dichloromethane, trichloroethane, 
trichloroethylene and the ion transitions 84→84, 86→86, 129→129 and 131→131 
Figure 2
Figure 3: Chromatograms coming from volunteer 2 (30% xenon/60% oxygen/10% air for 45 
minutes) immediateley after inhalation of xenon 
Figure 3
Table 1. Results from the method validation 
Range [2.08 – 104 nmol] 
Day 1 Day 2 Day 3 
Slope 0.262 0.045 0.041 
Intercept - 0.456 0.089 0.058 
R
2
0.996 0.992 0.991 
Range [2.08 – 104 nmol] 
Target value 3.64 7.28 18.2 36.4 72.4 
Level average 2.033 3.987 21.26 39.37 72.28 
Bias - 44% - 45% 17% 8% - 1% 
Lower limit 0.998 2.641 19.27 36.00 69.93 
Upper limit 3.068 5.334 23.26 42.73 74.64 
CVr 23.77% 15.77% 6.34% 5.43% 2.28% 
CVR 23.70% 16.15% 6.35% 5.19% 2.11% 
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